Literature DB >> 10393862

Development of hyperplasias, preneoplasias, and mammary tumors in MMTV-c-erbB-2 and MMTV-TGFalpha transgenic rats.

B R Davies1, A M Platt-Higgins, G Schmidt, P S Rudland.   

Abstract

Human cDNAs corresponding to two epidermal growth factor-related products that are overexpressed in human breast cancers, that for c-erbB-2 (HER-2) and for transforming growth factor alpha (TGFalpha), have been cloned downstream of the mouse mammary tumor virus (MMTV) long terminal repeat promoter and injected into the pronucleus of fertilized oocytes of Sprague-Dawley rats to produce transgenic offspring. Expression of the transgenic mRNAs is not detectable in mammary tissue from virgin transgenic rats but is detected in mammary tissue from certain lines of mid-pregnant transgenic rats. When two such lines of either type of transgenic rat are subjected to repeated cycles of pregnancy and lactation, they produce, primarily in the mammary glands, extensive pathologies, whereas virgin transgenic rats produce no such abnormalities. Multiparous transgenic female offspring from c-erbB-2-expressing lines develop a variety of focal hyperplastic and benign lesions that resemble lesions commonly found in human breasts. These lesions include lobular and ductal hyperplasia, fibroadenoma, cystic expansions, and papillary adenomas. More malignant lesions, including ductal carcinoma in situ and carcinoma, also develop stochastically at low frequency. The mammary glands of transgenic females invariably fail to involute fully after lactation. Similar phenotypes are observed in female MMTV-TGFalpha transgenic rats. In addition, multiparous TGFalpha-expressing female transgenics frequently develop severe pregnancy-dependent lactating hyperplasias as well as residual lobules of hyperplastic secretory epithelium and genuine lactating adenomas after weaning. These transgenic rat models confirm the conclusions reached in transgenic mice that overexpression of the c-erbB-2 and TGFalpha genes predisposes the mammary gland to stochastic tumor development.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10393862      PMCID: PMC1866674          DOI: 10.1016/s0002-9440(10)65124-3

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  49 in total

Review 1.  Comparative study of human and rat mammary tumorigenesis.

Authors:  J Russo; B A Gusterson; A E Rogers; I H Russo; S R Wellings; M J van Zwieten
Journal:  Lab Invest       Date:  1990-03       Impact factor: 5.662

2.  Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer.

Authors:  M J van de Vijver; J L Peterse; W J Mooi; P Wisman; J Lomans; O Dalesio; R Nusse
Journal:  N Engl J Med       Date:  1988-11-10       Impact factor: 91.245

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Expression of neu protein, epidermal growth factor receptor, and transforming growth factor alpha in breast cancer. Correlation with clinicopathologic parameters.

Authors:  J Lundy; A Schuss; D Stanick; E S McCormack; S Kramer; J M Sorvillo
Journal:  Am J Pathol       Date:  1991-06       Impact factor: 4.307

5.  Development of mammary hyperplasia and neoplasia in MMTV-TGF alpha transgenic mice.

Authors:  Y Matsui; S A Halter; J T Holt; B L Hogan; R J Coffey
Journal:  Cell       Date:  1990-06-15       Impact factor: 41.582

6.  Factors affecting the efficiency of introducing foreign DNA into mice by microinjecting eggs.

Authors:  R L Brinster; H Y Chen; M E Trumbauer; M K Yagle; R D Palmiter
Journal:  Proc Natl Acad Sci U S A       Date:  1985-07       Impact factor: 11.205

7.  Inhibition of mammary gland involution is associated with transforming growth factor alpha but not c-myc-induced tumorigenesis in transgenic mice.

Authors:  E P Sandgren; J A Schroeder; T H Qui; R D Palmiter; R L Brinster; D C Lee
Journal:  Cancer Res       Date:  1995-09-01       Impact factor: 12.701

8.  Transforming growth factor-alpha promotes mammary tumorigenesis through selective survival and growth of secretory epithelial cells.

Authors:  G H Smith; R Sharp; E C Kordon; C Jhappan; G Merlino
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

9.  The int-2 gene product acts as an epithelial growth factor in transgenic mice.

Authors:  W J Muller; F S Lee; C Dickson; G Peters; P Pattengale; P Leder
Journal:  EMBO J       Date:  1990-03       Impact factor: 11.598

10.  c-erbB-2 expression in benign and malignant breast disease.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; C Elliott; S Ashley; P Monaghan; S Harrison
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

View more
  10 in total

Review 1.  Transgenic modifications of the rat genome.

Authors:  Laurent Tesson; Jean Cozzi; Séverine Ménoret; Séverine Rémy; Claire Usal; Alexandre Fraichard; Ignacio Anegon
Journal:  Transgenic Res       Date:  2005-10       Impact factor: 2.788

2.  Mouse Models of Overexpression Reveal Distinct Oncogenic Roles for Different Type I Protein Arginine Methyltransferases.

Authors:  Jianqiang Bao; Alessandra Di Lorenzo; Kevin Lin; Yue Lu; Yi Zhong; Manu M Sebastian; William J Muller; Yanzhong Yang; Mark T Bedford
Journal:  Cancer Res       Date:  2018-10-23       Impact factor: 12.701

Review 3.  Genetically engineered mouse models of mammary intraepithelial neoplasia.

Authors:  R D Cardiff; D Moghanaki; R A Jensen
Journal:  J Mammary Gland Biol Neoplasia       Date:  2000-10       Impact factor: 2.673

4.  Benign breast disease heterogeneity: association with histopathology, age, and ethnicity.

Authors:  Jingfang Cheng; Shijing Qiu; Usha Raju; Sandra R Wolman; Maria J Worsham
Journal:  Breast Cancer Res Treat       Date:  2007-10-05       Impact factor: 4.872

5.  Strain background alters mammary gland lesion phenotype in transforming growth factor-alpha transgenic mice.

Authors:  Teresa A Rose-Hellekant; Kennedy Gilchrist; Eric P Sandgren
Journal:  Am J Pathol       Date:  2002-10       Impact factor: 4.307

Review 6.  Animal models of breast cancer for the study of pathogenesis and therapeutic insights.

Authors:  Angels Sierra
Journal:  Clin Transl Oncol       Date:  2009-11       Impact factor: 3.405

Review 7.  Breast cancer animal models and applications.

Authors:  Li Zeng; Wei Li; Ce-Shi Chen
Journal:  Zool Res       Date:  2020-09-18

Review 8.  Large Animal Models of Breast Cancer.

Authors:  Pinaki Mondal; Katie L Bailey; Sara B Cartwright; Vimla Band; Mark A Carlson
Journal:  Front Oncol       Date:  2022-02-04       Impact factor: 6.244

9.  S100A4 regulates cell motility and invasion in an in vitro model for breast cancer metastasis.

Authors:  S R Jenkinson; R Barraclough; C R West; P S Rudland
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

10.  Characterization of a murine xenograft model for contrast agent development in breast lesion malignancy assessment.

Authors:  Tsung-Hsien Yen; Gi-Da Lee; Jyn-Wen Chai; Jiunn-Wang Liao; Jia-Yu Lau; Li-Che Hu; Kuo-Chih Liao
Journal:  J Biomed Sci       Date:  2016-05-17       Impact factor: 8.410

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.